Today's Daily Dose brings you news about Adamis' prior approval supplement of allergy shot drug Symjepi; Aeglea's progress in Phase 1/2 clinical trial with Pegzilarginase; near-term catalyst of Protalix and NanoVibronix's trial results of its PainShield device in treating patients with Trigeminal Neuralgia (suicide disease).
from RTT - Biotech http://ift.tt/2zBDWlT
via IFTTT
No comments:
Post a Comment